Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRYPTYR in Sjögren's Syndrome-Related Dry Eye Disease
NCT07277257Phase 4
Key facts
- Status
- Recruiting
- Start
- Dec 2025
- Primary completion
- Dec 2026
- Countries
- 1
- Sponsor
- Center For Sight
- Modality
- Small Molecules
- Drugs
- acoltremon
- Conditions
- dry eye disease (DED)
01
Overview
Phase 4, open-label, single-arm trial of acoltremon in dry eye disease (DED), sponsored by Center For Sight. Primary endpoint: Unanesthetized Schirmer's test score at 3 minutes. Started Dec 2025; status: recruiting.
02
Design
1 arm- Study design
- Non-randomizedOpen-labelSingle group
Study eye
TRYPTYR (Acoltremon ophthalmic solution 0.003%) instilled in the eye with the lower pre-drop unanesthetized Schirmer score.
03
Who it enrols
Adults with dry eye disease secondary to Sjögren's Syndrome, with specific Schirmer's and tCFS scores, excluding those with recent ocular surgery, contact lens use, or recent topical steroids.
04
Endpoints
Primary
Unanesthetized Schirmer's test score
Beyond the preview
Go deeper on NCT07277257.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07277257.